Tagged with Vaccines,

Global Four companies (GSK, Pfizer, Sanofi, and MSD) together occupy over 80 percent of the global market for vaccines. Moreover, vaccines are an important part of these companies’ revenue streams, making up between 13 and 21 percent of total revenues in 2019.   Made with Visme Infographic Maker   Insights on Vaccines’…

Norway Sissel Lønning Andresen explains how Pfizer Norway has been a pioneer of digital communication channels for years, what other Pfizer affiliates can learn from Norway in this field, and how it helped in terms of working through the COVID-19 pandemic. Andresen also highlights her market access priorities, with the gene…

Global Scientists have come together in an unparalleled worldwide collaboration and sharing of data to advance a COVID-19 vaccine.[1] As rollouts become reality, stakeholders from across the globe will need to collaborate to ensure these vaccines are available and accepted. Vaccines will need a high level of trust for a return…

Global With several COVID-19 vaccines gaining regulatory approval across the world in record time, a spotlight has been shone on the vaccines field more widely, notably the 30-year wait for a HIV vaccine. Janssen Global Therapeutic Area Head of Vaccines Johan Van Hoof recently sat down with PharmaBoardroom to discuss the…

MEA The latest COVID-19 vaccine news from the Middle East & Africa (MEA) region, including the fallout from Iran’s ban on any imports of US- or UK-produced vaccines, Israel’s world-leading vaccination speed; and how Dubai Airports is working with GMR-Hyderabad to form a ‘vaccine corridor’.   Iran inks deal for Cuban…

China The latest from Chinese pharma, including domestic regulatory approval for Sinopharm’s COVID-19 vaccine, how the country’s online healthcare industry is booming in the wake of the pandemic, and news that companies are slashing prices on new products by an average of 51 percent in order for them to be covered…

Global Dr Thomas D. Madden, CEO and founder of Acuitas Therapeutics, shares the story behind their involvement in Pfizer and BioNTech’s COVID-19 vaccine, the numerous applications of the company’s proprietary lipid nanoparticle (LNP) delivery technology, as well as the growth strategy of the Canadian company.   We quickly recognized that the…

Norway Christian Probst gives an overview of GSK Norway’s broad portfolio, market access hurdles, and the importance of bringing clinical trials back to Norway. Probst also touches on how the country’s impressive digital footprint can be better leveraged and GSK’s role in Norway as one of the world’s leading vaccine companies.…

Global Dr Johan Van Hoof, global therapeutic area head of vaccines for Janssen, shares his extensive career experience in vaccines; the learnings from Janssen’s Ebola vaccine; and his key message to the global community on vaccines.   We need to be sure we are not complacent. We have to keep an…

South Africa South African firm Aspen has inked a deal with Johnson & Johnson for the technical transfer and proposed commercial manufacture of their COVID-19 vaccine candidate, Ad26.COV2-S, boosting the company’s share price as well as its global profile.   Aspen is best known internationally for bringing generic antiretrovirals for HIV to…

Global Epidemiologist John-Arne Røttingen has had a long and distinguished career in both academia and industry, including stints at Oslo, Oxford and Harvard universities, as well as helping coordinate the WHO’s response to the West African Ebola virus epidemic of 2013-2016 and being the founding CEO of the Coalition for Epidemic…

Global Sanofi CEO Paul Hudson ignited a heated debate around vaccine nationalism earlier this year when he suggested that the US, having made the biggest initial investment in Sanofi’s COVID-19 vaccine development, should have the first call on any vaccine that the firm was subsequently able to bring to market. In…